Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 8CNS 6Gastrointestinal 4Other hematologic neoplasm 3Myeloid 3Lymphoid 2Gynecologic 2Breast 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Ovarian Neoplasms 2

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × sonidegib × Gynecologic × Clear all
NCT02195973 2026-02-09

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

University of Alabama at Birmingham

Phase 1 Completed
15 enrolled
Gynecologic

Ovarian Neoplasms

NCT01954355 2019-12-06

LDE225 and Paclitaxel in Solid Tumors

Swiss Cancer Institute

Phase 1 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡